Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients.

The liposomal formulation of amphotericin B (AmBisome) greatly reduces the acute and chronic side effects of the parent drug. The present study describes the pharmacokinetic characteristics of AmBisome applied to 10 patients at a dose of 2.8 to 3.0 mg/kg of body weight and compares them to the pharm...

Disgrifiad llawn

Manylion Llyfryddiaeth

Cyhoeddwyd yn:	Antimicrob Agents Chemother
Prif Awduron:	Heinemann, V, Bosse, D, Jehn, U, Kähny, B, Wachholz, K, Debus, A, Scholz, P, Kolb, H J, Wilmanns, W
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	American Society for Microbiology (ASM) 1997
Pynciau:	Research Article
Mynediad Ar-lein:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC163899/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/9174183/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.41.6.1275
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!